Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
Individuals with HS at ASCVD < 7.5% risk had similar CAD characteristics as patients without HS at < 7.5% ASCVD risk, yet experienced comparable MACE rates as those at ASCVD ≥ 7.5%.
Authors
- Svati H. Shah (ORCID: https://orcid.org/0000-0002-3495-2830)
- Kathleen E. Corey (ORCID: https://orcid.org/0000-0003-2882-7264)
- Júlia Karády (ORCID: https://orcid.org/0000-0002-6640-6260)
- Borek Foldyna (ORCID: https://orcid.org/0000-0002-2466-4827)
- Nandini M. Meyersohn (ORCID: https://orcid.org/0000-0001-9826-1097)
- Pamela S. Douglas (ORCID: https://orcid.org/0000-0001-9876-4049)
- Thomas Mayrhofer (ORCID: https://orcid.org/0000-0001-6287-5185)
- Michael T. Lu (ORCID: https://orcid.org/0000-0003-4696-9610)
- Maros Ferencik (ORCID: https://orcid.org/0000-0001-5872-2223)
- Neha Jadeja Pagidipati (ORCID: https://orcid.org/0000-0002-5004-8868)
- Udo Hoffmann
- Oluwafemi Balogon
Institutions
- Semmelweis University (HU)
- Harvard University (US)
- Oregon Health & Science University (US)
- Duke University (US)
- Massachusetts General Hospital (US)
- Clinical Research Institute (US)
- University of Applied Sciences Stralsund (DE)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1111/apt.18415
- Citations
- 2
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- American Heart Association
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- Gilead Sciences
- Alnylam Pharmaceuticals
- Kowa Company
- Novo Nordisk
- Esperion Therapeutics
- National Institutes of Health
- National Heart, Lung, and Blood Institute